182 related articles for article (PubMed ID: 25016799)
21. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.
Abdel-Wahab O; Levine RL
Blood; 2013 May; 121(18):3563-72. PubMed ID: 23640996
[TBL] [Abstract][Full Text] [Related]
22. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia.
Chan SM; Majeti R
Int J Hematol; 2013 Dec; 98(6):648-57. PubMed ID: 23949914
[TBL] [Abstract][Full Text] [Related]
23. Successful Treatment of Cytogenetically Normal Acute Myeloid Leukemia With Ten-Eleven Translocation 2-Isocitrate Dehydrogenase 2 and Additional Sex Comb-like 1-Nucleophosmin Co-mutations by HLA Haploidentical Stem Cell Transplantation: A Case Report and Literature Review.
Liu Y; Cao Y; Lin Y; Dong WM; Lin RR; Gu Q; Xie XB; Gu WY
Transplant Proc; 2018 Apr; 50(3):959-963. PubMed ID: 29661468
[TBL] [Abstract][Full Text] [Related]
24. Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group.
Ho PA; Kutny MA; Alonzo TA; Gerbing RB; Joaquin J; Raimondi SC; Gamis AS; Meshinchi S
Pediatr Blood Cancer; 2011 Aug; 57(2):204-9. PubMed ID: 21504050
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic aberrations in myeloid malignancies (Review).
Takahashi S
Int J Mol Med; 2013 Sep; 32(3):532-8. PubMed ID: 23760684
[TBL] [Abstract][Full Text] [Related]
26. Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents.
DiNardo CD; Patel KP; Garcia-Manero G; Luthra R; Pierce S; Borthakur G; Jabbour E; Kadia T; Pemmaraju N; Konopleva M; Faderl S; Cortes J; Kantarjian HM; Ravandi F
Leuk Lymphoma; 2014 Aug; 55(8):1925-9. PubMed ID: 24138309
[No Abstract] [Full Text] [Related]
27. GADD45A methylation predicts poor overall survival in acute myeloid leukemia and is associated with IDH1/2 and DNMT3A mutations.
Perugini M; Iarossi DG; Kok CH; Cummings N; Diakiw SM; Brown AL; Danner S; Bardy P; Bik To L; Wei AH; Lewis ID; D'Andrea RJ
Leukemia; 2013 Jul; 27(7):1588-92. PubMed ID: 23187294
[No Abstract] [Full Text] [Related]
28. DNA methylation and hydroxymethylation patterns in acute myeloid leukemia patients with mutations in DNMT3A and IDH1/2 and their combinations.
Šestáková Š; Krejčík Z; Folta A; Cerovská E; Šálek C; Merkerová MD; Pecherková P; Ráčil Z; Mayer J; Cetkovský P; Remešová H
Cancer Biomark; 2019; 25(1):43-51. PubMed ID: 30988238
[TBL] [Abstract][Full Text] [Related]
29. Interpreting new molecular genetics in myelodysplastic syndromes.
Abdel-Wahab O; Figueroa ME
Hematology Am Soc Hematol Educ Program; 2012; 2012():56-64. PubMed ID: 23233561
[TBL] [Abstract][Full Text] [Related]
30. Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.
Tibes R; Bogenberger JM; Benson KL; Mesa RA
Mol Diagn Ther; 2012 Oct; 16(5):269-83. PubMed ID: 23023734
[TBL] [Abstract][Full Text] [Related]
31. Deep Sequencing of Acute Myeloid Leukemia Reveals Driver Mutations and New Targets.
Brower V
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26864927
[No Abstract] [Full Text] [Related]
32. Genetic biomarkers in acute myeloid leukemia: will the promise of improving treatment outcomes be realized?
Yang J; Schiffer CA
Expert Rev Hematol; 2012 Aug; 5(4):395-407. PubMed ID: 22992234
[TBL] [Abstract][Full Text] [Related]
33. Molecular pathogenesis of AML: translating insights to the clinic.
Levine RL
Best Pract Res Clin Haematol; 2013 Sep; 26(3):245-8. PubMed ID: 24309525
[TBL] [Abstract][Full Text] [Related]
34. ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.
Paschka P; Schlenk RF; Gaidzik VI; Herzig JK; Aulitzky T; Bullinger L; Späth D; Teleanu V; Kündgen A; Köhne CH; Brossart P; Held G; Horst HA; Ringhoffer M; Götze K; Nachbaur D; Kindler T; Heuser M; Thol F; Ganser A; Döhner H; Döhner K
Haematologica; 2015 Mar; 100(3):324-30. PubMed ID: 25596267
[TBL] [Abstract][Full Text] [Related]
35. Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2.
Eisfeld AK; Kohlschmidt J; Mrózek K; Blachly JS; Nicolet D; Kroll K; Orwick S; Carroll AJ; Stone RM; de la Chapelle A; Byrd JC; Bloomfield CD
Leukemia; 2016 Nov; 30(11):2254-2258. PubMed ID: 27435003
[No Abstract] [Full Text] [Related]
36. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.
Brecqueville M; Rey J; Bertucci F; Coppin E; Finetti P; Carbuccia N; Cervera N; Gelsi-Boyer V; Arnoulet C; Gisserot O; Verrot D; Slama B; Vey N; Mozziconacci MJ; Birnbaum D; Murati A
Genes Chromosomes Cancer; 2012 Aug; 51(8):743-55. PubMed ID: 22489043
[TBL] [Abstract][Full Text] [Related]
37. DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice.
Scourzic L; Couronné L; Pedersen MT; Della Valle V; Diop M; Mylonas E; Calvo J; Mouly E; Lopez CK; Martin N; Fontenay M; Bender A; Guibert S; Dubreuil P; Dessen P; Droin N; Pflumio F; Weber M; Gaulard P; Helin K; Mercher T; Bernard OA
Leukemia; 2016 Jun; 30(6):1388-98. PubMed ID: 26876596
[TBL] [Abstract][Full Text] [Related]
38. Implications of Mutation Profiling in Myeloid Malignancies-PART 1: Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Tremblay D; Sokol K; Bhalla S; Rampal R; Mascarenhas JO
Oncology (Williston Park); 2018 Apr; 32(4):e38-e44. PubMed ID: 29684235
[TBL] [Abstract][Full Text] [Related]
39. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.
Rocquain J; Carbuccia N; Trouplin V; Raynaud S; Murati A; Nezri M; Tadrist Z; Olschwang S; Vey N; Birnbaum D; Gelsi-Boyer V; Mozziconacci MJ
BMC Cancer; 2010 Aug; 10():401. PubMed ID: 20678218
[TBL] [Abstract][Full Text] [Related]
40. Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia.
Hou HA; Liu CY; Kuo YY; Chou WC; Tsai CH; Lin CC; Lin LI; Tseng MH; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Huang SY; Ko BS; Hsu SC; Chen CY; Lin CT; Wu SJ; Tsay W; Tien HF
Oncotarget; 2016 Feb; 7(8):9084-101. PubMed ID: 26812887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
